Korea Research Institute of Chemical Technology has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) and mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) inhibitors reported to be useful for the treatment of Parkinson's disease, viral infection, cancer, tuberculosis and non-alcoholic steatohepatitis.
Triple-negative breast cancer (TNBC) is the most aggressive breast tumor subtype and despite treatment advances, still has shorter median overall survival rates and higher recurrence and metastatic rates than other subtypes, due to resistance to chemotherapy.
Carisma Therapeutics Inc. has received FDA clearance of its IND application for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor (CAR)-monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).
Researchers from Karolinska Institutet and collaborators have reported on the characterization of novel human anti-CD44v6 antibodies aimed to be used as anticancer agents in the radiotherapy of CD44v6-expressing cancers.
Vidac Pharma Holding plc has announced results from an in vitro study of VDA-1275 in combination with chemotherapeutic agents to treat solid tumors. VDA-1275 is a potent small molecule that reverses cancer cell hyper glycolytic metabolism (Warburg effect).
Previous research has demonstrated the promise of using carbon monoxide (CO) as an anticancer therapeutic agent, with reactive oxygen species (ROS)-activated CO prodrugs representing a new targeted cancer treatment strategy. In the current study, researchers from Georgia State University presented the discovery and preclinical evaluation of novel ROS-activated metal-free CO prodrugs.
Reports of T-cell malignancies, including lymphoma, have the U.S. FDA investigating the risks for patients who received certain autologous CAR T-cell immunotherapies.
Cancer Research UK (CRUK) is worried that rising prices and its total dependence on public donations mean its funding model is becoming unsustainable. The charity is calling on the U.K. government to step in and plug a £1 billion (US$1.23 billion) shortfall it said will open up over the next decade, in order to maintain investment at 2019 levels in real terms.
Springworks Therapeutics Inc.’s nirogacestat became the first drug indicated specifically for desmoid tumors, as well as the first gamma-secretase inhibitor to win marketing approval, winning a U.S. FDA nod on the anticipated PDUFA date of Nov. 27. Branded Ogsiveo, nirogacestat has breakthrough therapy, fast track and orphan designations.
In less than one week, Innovent Biologics Inc. has seen two NDAs for non-small-cell lung cancer accepted for review by China’s National Medical Products Administration, and both are firsts for China. The NDA for IBI-351 under priority review marks China’s first NDA for a KRAS G12C inhibitor, and the NDA for taletrectinib is the first global submission for the ROS1 inhibitor.
RSS
